{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,4,5]],"date-time":"2022-04-05T07:34:59Z","timestamp":1649144099640},"reference-count":42,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2019,12,1]],"date-time":"2019-12-01T00:00:00Z","timestamp":1575158400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Pediatric Surgery"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1016\/j.sempedsurg.2019.150863","type":"journal-article","created":{"date-parts":[[2019,11,20]],"date-time":"2019-11-20T12:12:00Z","timestamp":1574251920000},"page":"150863","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Complications of biologic therapy for pediatric cancer \u2013 What the surgeon needs to know"],"prefix":"10.1016","volume":"28","author":[{"given":"Marcus M.","family":"Malek","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.sempedsurg.2019.150863_bib0001","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3322\/caac.21332","article-title":"Cancer statistics, 2016","volume":"66","author":"Siegel","year":"2016","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.sempedsurg.2019.150863_bib0002","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3322\/caac.21387","article-title":"Cancer statistics, 2017","volume":"67","author":"Siegel","year":"2017","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.sempedsurg.2019.150863_bib0003","doi-asserted-by":"crossref","first-page":"2371","DOI":"10.1001\/jama.2013.6296","article-title":"Clinical ascertainment of health outcomes among adults treated for childhood cancer","volume":"309","author":"Hudson","year":"2013","journal-title":"JAMA"},{"key":"10.1016\/j.sempedsurg.2019.150863_bib0004","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1097\/MOP.0000000000000570","article-title":"Precision medicine in pediatric oncology","volume":"30","author":"Forrest","year":"2018","journal-title":"Curr Opin Pediatr"},{"key":"10.1016\/j.sempedsurg.2019.150863_bib0005","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1056\/NEJMoa022457","article-title":"Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia","volume":"348","author":"O'Brien","year":"2003","journal-title":"New Engl J Med"},{"key":"10.1016\/j.sempedsurg.2019.150863_bib0006","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1038\/leu.2014.30","article-title":"Long-term follow-up of imatinib in pediatric philadelphia chromosome-positive acute lymphoblastic leukemia: children's oncology group study AALL0031","volume":"28","author":"Schultz","year":"2014","journal-title":"Leukemia"},{"key":"10.1016\/j.sempedsurg.2019.150863_bib0007","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1056\/NEJMoa0911123","article-title":"Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma","volume":"363","author":"Yu","year":"2010","journal-title":"New Engl J Med"},{"key":"10.1016\/j.sempedsurg.2019.150863_bib0008","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/jnci\/djw274","article-title":"Target and agent prioritization for the children's oncology group-national cancer institute pediatric match trial","volume":"109","author":"Allen","year":"2017","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.sempedsurg.2019.150863_bib0009","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1038\/nrclinonc.2017.59","article-title":"Early phase clinical trials of anticancer agents in children and adolescents \u2013 an ITCC perspective","volume":"14","author":"Moreno","year":"2017","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.sempedsurg.2019.150863_bib0010","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1634\/theoncologist.12-4-443","article-title":"Target practice: lessons from phase iii trials with bevacizumab and vatalanib in the treatment of advanced colorectal cancer","volume":"12","author":"Los","year":"2007","journal-title":"Oncologist"},{"key":"10.1016\/j.sempedsurg.2019.150863_bib0011","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1016\/j.ijrobp.2010.07.024","article-title":"Phase ii study of neoadjuvant bevacizumab and radiotherapy for resectable soft tissue sarcomas","volume":"81","author":"Yoon","year":"2011","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.sempedsurg.2019.150863_bib0012","doi-asserted-by":"crossref","first-page":"2455","DOI":"10.1002\/cncr.22298","article-title":"Complications of combined modality treatment of primary lower extremity soft-tissue sarcomas","volume":"107","author":"Cannon","year":"2006","journal-title":"Cancer"},{"key":"10.1016\/j.sempedsurg.2019.150863_bib0013","doi-asserted-by":"crossref","first-page":"2824","DOI":"10.1245\/s10434-015-4631-z","article-title":"The influence of time interval between preoperative radiation and surgical resection on the development of wound healing complications in extremity soft tissue sarcoma","volume":"22","author":"Griffin","year":"2015","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.sempedsurg.2019.150863_bib0014","doi-asserted-by":"crossref","first-page":"2235","DOI":"10.1016\/S0140-6736(02)09292-9","article-title":"Preoperative versus postoperative radiotherapy in soft-tissue sarcoma of the limbs: a randomised trial","volume":"359","author":"O'Sullivan","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.sempedsurg.2019.150863_bib0015","first-page":"1671","article-title":"Major wound complication risk factors following soft tissue sarcoma resection","volume":"40","author":"Moore","year":"2014","journal-title":"Eur J Surg Oncol J Eur Soc Surg Oncol Br Assoc Surg Oncol"},{"key":"10.1016\/j.sempedsurg.2019.150863_bib0016","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1245\/s10434-006-9028-6","article-title":"The effect of preoperative radiotherapy and reconstructive surgery on wound complications after resection of extremity soft-tissue sarcomas","volume":"13","author":"Tseng","year":"2006","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.sempedsurg.2019.150863_bib0017","doi-asserted-by":"crossref","first-page":"2231","DOI":"10.1200\/JCO.2014.58.5828","article-title":"Significant reduction of late toxicities in patients with extremity sarcoma treated with image-guided radiation therapy to a reduced target volume: results of radiation therapy oncology group RTOG-0630 trial","volume":"33","author":"Wang","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.sempedsurg.2019.150863_bib0018","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.1016\/S0140-6736(12)60651-5","article-title":"Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial","volume":"379","author":"van der Graaf","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.sempedsurg.2019.150863_bib0019","unstructured":"National Cancer Institute. Radiation therapy with or without combination chemotherapy or pazopanib hydrochloride before surgery in treating patients with newly diagnosed non-rhabdomyosarcoma soft tissue sarcomas that can be removed by surgery: https:\/\/ClinicalTrials.gov\/show\/NCT02180867; 2014."},{"key":"10.1016\/j.sempedsurg.2019.150863_bib0020","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1097\/01.sla.0000133083.54934.ae","article-title":"Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey","volume":"240","author":"Dindo","year":"2004","journal-title":"Ann Surg"},{"key":"10.1016\/j.sempedsurg.2019.150863_bib0021","doi-asserted-by":"crossref","first-page":"1878","DOI":"10.1002\/cncr.27951","article-title":"Phase 2 study of preoperative image-guided intensity-modulated radiation therapy to reduce wound and combined modality morbidities in lower extremity soft tissue sarcoma","volume":"119","author":"O'Sullivan","year":"2013","journal-title":"Cancer"},{"key":"10.1016\/j.sempedsurg.2019.150863_bib0022","doi-asserted-by":"crossref","first-page":"1","DOI":"10.12688\/f1000research.9207.1","article-title":"mTOR inhibitors in cancer therapy","volume":"5","author":"Xie","year":"2016","journal-title":"F1000Res"},{"key":"10.1016\/j.sempedsurg.2019.150863_bib0023","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.canlet.2012.01.005","article-title":"mTOR inhibitors in cancer therapy","volume":"319","author":"Zaytseva","year":"2012","journal-title":"Cancer Lett"},{"key":"10.1016\/j.sempedsurg.2019.150863_bib0024","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1097\/TP.0b013e3182551021","article-title":"Wound healing complications and the use of mammalian target of rapamycin inhibitors in kidney transplantation: a critical review of the literature","volume":"94","author":"Nashan","year":"2012","journal-title":"Transplantation"},{"key":"10.1016\/j.sempedsurg.2019.150863_bib0025","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1111\/j.1432-2277.2011.01357.x","article-title":"Do wound complications or lymphoceles occur more often in solid organ transplant recipients on mTOR inhibitors? a systematic review of randomized controlled trials","volume":"24","author":"Pengel","year":"2011","journal-title":"Transpl Int"},{"key":"10.1016\/j.sempedsurg.2019.150863_bib0026","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1097\/01.tp.0000219703.39149.85","article-title":"Target of rapamycin inhibitors (sirolimus and everolimus) for primary immunosuppression of kidney transplant recipients: a systematic review and meta-analysis of randomized trials","volume":"81","author":"Webster","year":"2006","journal-title":"Transplantation"},{"key":"10.1016\/j.sempedsurg.2019.150863_bib0027","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1097\/TP.0b013e3181aa7d87","article-title":"Incidence of delayed graft function and wound healing complications after deceased-donor kidney transplantation is not affected by de novo everolimus","volume":"88","author":"Albano","year":"2009","journal-title":"Transplantation"},{"key":"10.1016\/j.sempedsurg.2019.150863_bib0028","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1111\/j.1432-2277.2010.01094.x","article-title":"Efficacy and safety of de novo or early everolimus with low cyclosporine in deceased-donor kidney transplant recipients at specified risk of delayed graft function: 12-month results of a randomized, multicenter trial","volume":"23","author":"Dantal","year":"2010","journal-title":"Transpl Int"},{"key":"10.1016\/j.sempedsurg.2019.150863_bib0029","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.gore.2018.08.005","article-title":"Recurrent colon perforation after discontinuation of bevacizumab for ovarian cancer","volume":"26","author":"Nonaka","year":"2018","journal-title":"Gynecol Oncol Rep"},{"key":"10.1016\/j.sempedsurg.2019.150863_bib0030","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1016\/j.gie.2011.06.008","article-title":"GI perforation associated with bevacizumab","volume":"75","author":"Yoon","year":"2012","journal-title":"Gastrointest Endosc"},{"key":"10.1016\/j.sempedsurg.2019.150863_bib0031","doi-asserted-by":"crossref","first-page":"5180","DOI":"10.1200\/JCO.2007.12.0782","article-title":"Phase ii study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer","volume":"25","author":"Cannistra","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.sempedsurg.2019.150863_bib0032","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1016\/S1470-2045(09)70112-3","article-title":"Risk of gastrointestinal perforation in patients with cancer treated with bevacizumab: a meta-analysis","volume":"10","author":"Hapani","year":"2009","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.sempedsurg.2019.150863_bib0033","doi-asserted-by":"crossref","first-page":"1424","DOI":"10.1200\/JCO.18.02374","article-title":"Randomized double-blind phase ii study of regorafenib in patients with metastatic osteosarcoma","volume":"37","author":"Davis","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.sempedsurg.2019.150863_bib0034","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.ygyno.2010.05.033","article-title":"A phase II, open-label study evaluating pazopanib in patients with recurrent ovarian cancer","volume":"119","author":"Friedlander","year":"2010","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.sempedsurg.2019.150863_bib0035","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1016\/S1470-2045(12)70294-2","article-title":"Pazopanib in advanced and platinum-resistant urothelial cancer: an open-label, single group, phase 2 trial","volume":"13","author":"Necchi","year":"2012","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.sempedsurg.2019.150863_bib0036","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1016\/j.clgc.2013.05.005","article-title":"A phase ii safety and efficacy study of the vascular endothelial growth factor receptor tyrosine kinase inhibitor pazopanib in patients with metastatic urothelial cancer","volume":"11","author":"Pili","year":"2013","journal-title":"Clin Genitourin Cancer"},{"key":"10.1016\/j.sempedsurg.2019.150863_bib0037","doi-asserted-by":"crossref","first-page":"113","DOI":"10.3109\/0284186X.2013.794957","article-title":"Pazopanib after sunitinib failure in patients with metastatic renal cell carcinoma","volume":"53","author":"Rautiola","year":"2014","journal-title":"Acta Oncol"},{"key":"10.1016\/j.sempedsurg.2019.150863_bib0038","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1016\/j.ejca.2012.12.010","article-title":"A randomised, double-blind phase iii study of pazopanib in patients with advanced and\/or metastatic renal cell carcinoma: final overall survival results and safety update","volume":"49","author":"Sternberg","year":"2013","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.sempedsurg.2019.150863_bib0039","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/2045-3329-4-14","article-title":"Pneumothorax as adverse event in patients with lung metastases of soft tissue sarcoma treated with pazopanib: a single reference centre case series","volume":"4","author":"Verschoor","year":"2014","journal-title":"Clin Sarcoma Res"},{"key":"10.1016\/j.sempedsurg.2019.150863_bib0040","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1186\/s12885-018-4858-8","article-title":"Secondary spontaneous pneumothorax in patients with sarcoma treated with pazopanib, a case control study","volume":"18","author":"Sabath","year":"2018","journal-title":"BMC Cancer"},{"key":"10.1016\/j.sempedsurg.2019.150863_bib0041","unstructured":"National Cancer Institute. Cabozantinib S-malate in treating patients with relapsed osteosarcoma or Ewing sarcoma: https:\/\/ClinicalTrials.gov\/show\/NCT02243605; 2014."},{"key":"10.1016\/j.sempedsurg.2019.150863_bib0042","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2017.35.15_suppl.11005","article-title":"A phase ii trial of regorafenib (REGO) in patients (pts) with advanced ewing sarcoma and related tumors (EWS) of soft tissue and bone: SARC024 trial results","volume":"35","author":"Attia","year":"2017","journal-title":"J Clin Oncol"}],"container-title":["Seminars in Pediatric Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1055858619301210?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1055858619301210?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,1,8]],"date-time":"2020-01-08T02:25:32Z","timestamp":1578450332000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1055858619301210"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12]]},"references-count":42,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["S1055858619301210"],"URL":"https:\/\/doi.org\/10.1016\/j.sempedsurg.2019.150863","relation":{},"ISSN":["1055-8586"],"issn-type":[{"value":"1055-8586","type":"print"}],"subject":[],"published":{"date-parts":[[2019,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Complications of biologic therapy for pediatric cancer \u2013 What the surgeon needs to know","name":"articletitle","label":"Article Title"},{"value":"Seminars in Pediatric Surgery","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.sempedsurg.2019.150863","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"150863"}}